Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 291

1.

A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab.

Wehrli SJ, Tawse K, Levin MH, Zaidi A, Pistilli M, Brucker AJ.

Retina. 2012 Jul;32(7):1295-301. doi: 10.1097/IAE.0b013e31823f0c95.

PMID:
22466465
2.

Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.

Hoang QV, Tsuang AJ, Gelman R, Mendonca LS, Della Torre KE, Jung JJ, Freund KB.

Retina. 2013 Jan;33(1):179-87. doi: 10.1097/IAE.0b013e318261a6f7.

PMID:
22990314
3.

Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.

Hoang QV, Mendonca LS, Della Torre KE, Jung JJ, Tsuang AJ, Freund KB.

Ophthalmology. 2012 Feb;119(2):321-6. doi: 10.1016/j.ophtha.2011.08.011. Epub 2011 Nov 4.

PMID:
22054994
4.

Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration.

Mathalone N, Arodi-Golan A, Sar S, Wolfson Y, Shalem M, Lavi I, Geyer O.

Graefes Arch Clin Exp Ophthalmol. 2012 Oct;250(10):1435-40. doi: 10.1007/s00417-012-1981-0. Epub 2012 Mar 21.

PMID:
22434210
5.

Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents.

Good TJ, Kimura AE, Mandava N, Kahook MY.

Br J Ophthalmol. 2011 Aug;95(8):1111-4. doi: 10.1136/bjo.2010.180729. Epub 2010 Aug 11.

PMID:
20702430
6.

Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure.

Kim YJ, Sung KR, Lee KS, Joe SG, Lee JY, Kim JG, Yoon YH.

Am J Ophthalmol. 2014 Jun;157(6):1266-1271.e1. doi: 10.1016/j.ajo.2014.02.035. Epub 2014 Feb 18.

PMID:
24561173
7.

Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab.

Segal O, Ferencz JR, Cohen P, Nemet AY, Nesher R.

Isr Med Assoc J. 2013 Jul;15(7):352-5.

8.

Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.

Tseng JJ, Vance SK, Della Torre KE, Mendonca LS, Cooney MJ, Klancnik JM, Sorenson JA, Freund KB.

J Glaucoma. 2012 Apr-May;21(4):241-7. doi: 10.1097/IJG.0b013e31820d7d19.

PMID:
21423038
9.

INCIDENCE OF SUSTAINED OCULAR HYPERTENSION USING PREPACKAGED VERSUS FRESHLY PREPARED INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

Storey PP, Ho V, Yeh S, Reddy S, Fang-Yen NH, Pequignot E, Leiby BE, Fineman M, Garg S, Hubbard GB 3rd, Hsu J.

Retina. 2015 Oct;35(10):1992-2000. doi: 10.1097/IAE.0000000000000620.

PMID:
26035396
10.

Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials.

Bakri SJ, Moshfeghi DM, Francom S, Rundle AC, Reshef DS, Lee PP, Schaeffer C, Rubio RG, Lai P.

Ophthalmology. 2014 May;121(5):1102-8. doi: 10.1016/j.ophtha.2013.11.029. Epub 2014 Jan 6.

PMID:
24393349
11.

Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections.

Adelman RA, Zheng Q, Mayer HR.

J Ocul Pharmacol Ther. 2010 Feb;26(1):105-10. doi: 10.1089/jop.2009.0076.

PMID:
20187807
12.

Intraocular Pressure in Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept or Ranibizumab.

Freund KB, Hoang QV, Saroj N, Thompson D.

Ophthalmology. 2015 Sep;122(9):1802-10. doi: 10.1016/j.ophtha.2015.04.018. Epub 2015 May 27.

PMID:
26025097
13.

Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.

Choi DY, Ortube MC, McCannel CA, Sarraf D, Hubschman JP, McCannel TA, Gorin MB.

Retina. 2011 Jun;31(6):1028-35. doi: 10.1097/IAE.0b013e318217ffde.

PMID:
21836409
14.

Intravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuity.

Axer-Siegel R, Bor E, Bourla DH, Weinberger D, Mimouni K.

Retina. 2012 Oct;32(9):1811-20.

PMID:
22825407
15.

SUSTAINED ELEVATION OF INTRAOCULAR PRESSURE AFTER INTRAVITREAL ANTI-VEGF AGENTS: What Is the Evidence?

Dedania VS, Bakri SJ.

Retina. 2015 May;35(5):841-58. doi: 10.1097/IAE.0000000000000520. Review.

PMID:
25905784
16.

Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments.

Rusu IM, Deobhakta A, Yoon D, Lee M, Slakter JS, Klancnik JM, Thompson D, Freund KB.

Retina. 2014 Nov;34(11):2161-6. doi: 10.1097/IAE.0000000000000264.

PMID:
25072648
17.

Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.

Saito M, Iida T, Kano M.

Retina. 2012 Jul;32(7):1250-9. doi: 10.1097/IAE.0b013e318236e503.

PMID:
22446886
18.

Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.

Frenkel MP, Haji SA, Frenkel RE.

Arch Ophthalmol. 2010 Dec;128(12):1523-7. doi: 10.1001/archophthalmol.2010.297. Erratum in: Arch Ophthalmol. 2011 Mar;129(3):275.

PMID:
21149773
19.

[Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].

Bidot ML, Malvitte L, Bidot S, Bron A, Creuzot-Garcher C.

J Fr Ophtalmol. 2011 Jun;34(6):376-81. doi: 10.1016/j.jfo.2011.03.004. Epub 2011 May 7. French.

20.

Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis).

Sharei V, Höhn F, Köhler T, Hattenbach LO, Mirshahi A.

Eur J Ophthalmol. 2010 Jan-Feb;20(1):174-9.

PMID:
19927267

Supplemental Content

Support Center